Quarterly report pursuant to Section 13 or 15(d)

Development Award and Deferred Revenue (Details Narrative)

Development Award and Deferred Revenue (Details Narrative)						1 Months Ended			3 Months Ended
	Jan. 26, 2018 USD ($) $ / shares shares	Jan. 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Apr. 20, 2015 USD ($) Installments	Apr. 20, 2015 USD ($) Installments	Nov. 30, 2017 USD ($)	Nov. 30, 2015 USD ($)	May 31, 2015 USD ($)	Mar. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2017 USD ($)
Development Award [Line Items]
Amount received upon achievement									$ 6,250,000
Revenue									$ 950,442	$ 1,293,697
Warrant to purchase of common stock \| shares									2,288,500
Warrant exercisable price per sahre \| $ / shares									$ 6.33
Reclassified to contract asset and classified in prepaid expenses									$ 915,667
Additional paid in capital, fair value of warrant issued									6,215,225
Phase 2b Clinical Trial [Member]
Development Award [Line Items]
Amount received upon achievement	$ 6,250,000
Cystic Fibrosis Foundation warrants [Member]
Development Award [Line Items]
Revenue									$ 18,784,775
Warrant to purchase of common stock \| shares	1,000,000								1,000,000
Warrant exercisable price per sahre \| $ / shares	$ 13.20								$ 13.20
Warrant exercisable shares of common stock \| shares	500,000								500,000
Warrant expires date	Jan. 26, 2025
Additional paid in capital, fair value of warrant issued									$ 6,215,225
2015 CFFT Award Agreement [Member]
Development Award [Line Items]
Amount received upon achievement		$ 1,000,000	$ 1,000,000			$ 500,000	$ 1,250,000	$ 1,250,000
Revenue										$ 1,293,697
2015 CFFT Award Agreement [Member] \| Oral Anti-inflammatory Drug [Member]
Development Award [Line Items]
Amount received upon achievement					$ 5,000,000
2015 CFFT Award Agreement [Member] \| Lenabasum [Member] \| Upon Reaching the Sales Target [Member]
Development Award [Line Items]
Payment due period after the first commercial sale				90 days
Number of installments \| Installments				3	3
Royalty payment, sales target				$ 500,000,000	$ 500,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member]
Development Award [Line Items]
Development award received				5,000,000	$ 5,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member] \| Lenabasum [Member] \| Upon Commercialization of the Product [Member]
Development Award [Line Items]
Royalty payable				25,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member] \| Lenabasum [Member] \| Upon Reaching the Sales Target [Member]
Development Award [Line Items]
Royalty payable				5,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member] \| Lenabasum [Member] \| Upon Transfer Sale or Licensing [Member]
Development Award [Line Items]
Royalty payable				$ 15,000,000
Cystic Fibrosis Program Related Investment Agreement [Member] \| Maximum [Member]
Development Award [Line Items]
Development award received	$ 25,000,000
Investment Agreement [Member]
Development Award [Line Items]
Revenue									950,442
Reclassified to contract asset and classified in prepaid expenses									$ 25,000,000
Investment Agreement [Member] \| Cystic Fibrosis Foundation warrants [Member]
Development Award [Line Items]
Warrant exercisable shares of common stock \| shares	500,000								500,000
Warrant expires date									Jan. 26, 2025
Investment Agreement [Member] \| May 2018 [Member] \| Phase 2b Clinical Trial [Member]
Development Award [Line Items]
Amount received upon achievement	$ 6,250,000